Tuberculosis News and Research

Latest Tuberculosis News and Research

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

New method can pinpoint DNA mutations that could help treat cancer, tuberculosis

New method can pinpoint DNA mutations that could help treat cancer, tuberculosis

FDA allows marketing of Xpert MTB/RIF Assay for treatment of TB

FDA allows marketing of Xpert MTB/RIF Assay for treatment of TB

Researcher identify genetic mutation in Africans with HIV that puts them at higher risk for tuberculosis

Researcher identify genetic mutation in Africans with HIV that puts them at higher risk for tuberculosis

Cepheid, American Lung Association partner to promote TB awareness in U.S.

Cepheid, American Lung Association partner to promote TB awareness in U.S.

Serum Institute of India secures license to patents, technologies related to tuberculosis vaccine

Serum Institute of India secures license to patents, technologies related to tuberculosis vaccine

Understanding cancer at source could improve disease prevention

Understanding cancer at source could improve disease prevention

Metagenomics technique used to recover TB genomes from 215-year old mummy

Metagenomics technique used to recover TB genomes from 215-year old mummy

State highlights: D.C. health care providers continue wait for payments; Ga. plans Medicaid managed care for kids; Hospital chain seeks insurer license in Calif.

State highlights: D.C. health care providers continue wait for payments; Ga. plans Medicaid managed care for kids; Hospital chain seeks insurer license in Calif.

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

First Edition:  July 18, 2013

First Edition: July 18, 2013

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

University of North Carolina receives $8M grant to improve maternal and infant health

University of North Carolina receives $8M grant to improve maternal and infant health

Study identifies new groups of people at risk of parasitic lung infection

Study identifies new groups of people at risk of parasitic lung infection

Seattle researchers map critical molecules that regulate inflammation during flu infection

Seattle researchers map critical molecules that regulate inflammation during flu infection

Immune response to TB bacterium varies between patients of different ethnic origin

Immune response to TB bacterium varies between patients of different ethnic origin

Collaborative research yields a wiring map on how TB responds to changes in environment

Collaborative research yields a wiring map on how TB responds to changes in environment

Researchers produce potential antibiotic that targets bacterial enzyme critical to metabolic processes

Researchers produce potential antibiotic that targets bacterial enzyme critical to metabolic processes

Cannabis users appear to lack motivation

Cannabis users appear to lack motivation

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.